CytomX Therapeutics Inc. (CTMX)
NASDAQ:CTMX
Want to see CTMX full AI Analyst Report?
CTMX Stock Chart & Stats
$4.82
-$0.06(-5.83%)
At close: 4:00 PM EST
$4.82
-$0.06(-5.83%)
Day’s Range― - ―
52-Week Range$1.72 - $8.21
Previous CloseN/A
Volume1.08M
Average Volume (3M)3.28M
Market Cap
$687.94M
Enterprise Value$552.99M
Total Cash (Recent Filing)$346.71M
Total Debt (Recent Filing)$2.86M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 06, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding217,702,910
10 Day Avg. Volume3,664,851
30 Day Avg. Volume3,283,554
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.93
Price to Sales (P/S)7.71
P/FCF Ratio-7.75
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue15.56
Enterprise Value/Gross Profit15.67
Enterprise Value/Ebitda-8.95
Forecast
1Y Price Target
$12.30Price Target Upside155.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$29.88M
Bulls Say, Bears Say
Bulls Say
Varseta‑M EfficacyDurable clinical efficacy in late‑line metastatic CRC (ORR 20–32%, PFS ~7 months) suggests a differentiated therapeutic profile versus current single‑digit ORR competitors. Strong Phase I signals support a viable registrational path, partner interest, and long‑term commercial potential if durability and safety hold.
Cash RunwayA materially strengthened balance sheet with ~$347M and runway into H2 2028 reduces near‑term financing pressure, allowing prioritized investment in Varseta‑M and other programs. This funding window materially lowers execution risk for planned registrational activities and multiple clinical readouts over 2026–27.
Regeneron PartnershipExpansion of the Regeneron collaboration validates CytomX’s Probody platform and creates a substantial non‑dilutive funding and milestone pipeline. Access to Regeneron’s development and commercialization capabilities and potential tiered royalties support long‑term revenue optionality and technology leverage.
Bears Say
Cash BurnSustained TTM operating and free cash flow near -$80M highlight persistent negative cash generation. Absent durable product revenue, continued burn increases reliance on financings or milestone receipts, risking dilution or program slowdowns if capital markets or partner payments tighten over the medium term.
Revenue VolatilitySharp year‑over‑year revenue decline reflects dependence on timing of collaboration receipts. This episodic revenue profile reduces predictability of operating cash inflows, complicates multi‑year planning, and increases execution risk if milestone timing or new partnerships do not materialize as expected.
Clinical/regulatory RiskDose selection and safety (notably Grade‑3 diarrhea) are regulatory gates for a registrational design. If optimization fails to contain high‑grade events or OS data remain immature, the company may face dose reductions, delayed FDA interactions, or more onerous trial requirements, materially affecting timelines and commercial positioning.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
CytomX Therapeutics Inc. lowest stock price was $1.72 and its highest was $8.21 in the past 12 months.
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is $687.94M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.021.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.08.
How many shares outstanding does CytomX Therapeutics Inc. have?
CytomX Therapeutics Inc. has 217,702,910 shares outstanding.
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.30 (155.19% Upside)
$12.30 (155.19% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.69%
12-Months-Change
Fundamentals
Return on Equity
-36.61%
Trailing 12-Months
Asset Growth
264.84%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CTMX Company Deck
CTMX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$12.30
▲(155.19% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
Arcturus Therapeutics
―
KalVista Pharmaceuticals
―
Bicycle Therapeutics
―
Ownership Overview
0.91% Insiders
14.85% Mutual Funds
35.20% Other Institutional Investors
40.47% Public Companies and
Individual Investors